April 1, 2022

The Therapeutic Goods Administration (TGA), part of the Department of Health, has granted provisional determination to Vaxine Pty Ltd in relation to its COVID-19 vaccine: Recombinant CoV-2-S-ΔTM protein with Advax-CpG55.2 (active ingredient name and tradename to be confirmed).
This recombinant (genetically engineered) protein vaccine will be considered for active immunisation to prevent COVID-19 caused by SARS-CoV-2. If approved, a complete course of the Recombinant CoV-2-S-ΔTM protein with Advax-CpG55.2 vaccine is potentially two doses given as an intramuscular injection 3 weeks apart.
- Click to share on Facebook (Opens in new window)
- Click to share on Twitter (Opens in new window)
- Click to share on Telegram (Opens in new window)
- Click to share on LinkedIn (Opens in new window)
- Click to share on Reddit (Opens in new window)
- Click to share on WhatsApp (Opens in new window)
- Click to share on Skype (Opens in new window)
- Click to share on Tumblr (Opens in new window)
- Click to share on Pinterest (Opens in new window)
- Click to share on Pocket (Opens in new window)
- Click to email a link to a friend (Opens in new window)
- Click to print (Opens in new window)